https://scholar.dgist.ac.kr/handle/20.500.11750/8972 Sat, 04 Apr 2026 13:35:03 GMT 2026-04-04T13:35:03Z https://scholar.dgist.ac.kr/handle/20.500.11750/59240 Title: 사이토카인 및 항체를 발현하는 세포외 소포체, 이를 제조하는 방법 및 이의 용도 Author(s): 예경무; 백문창; 조한채 https://scholar.dgist.ac.kr/handle/20.500.11750/59240 https://scholar.dgist.ac.kr/handle/20.500.11750/59202 Title: METHOD FOR SCREENING FOR AGONIST ANTIBODIES THAT INDUCE RECEPTOR DIMERIZATION Author(s): 정인성; 정종원; 김지석; 박준국; 예경무 Abstract: The present invention relates to a method for screening for agonist antibodies that induce receptor dimerization. The screening method according to one embodiment enables the identification of agonist antibodies that mimic the signaling mechanism of natural signaling molecules and, in particular, enables complex screening for heterodimerization of single receptors or receptors that function by inducing homodimerization, and also of various types of receptors. https://scholar.dgist.ac.kr/handle/20.500.11750/59202 https://scholar.dgist.ac.kr/handle/20.500.11750/59163 Title: GFRAL antagonistic antibodies and uses thereof Author(s): 정종원; 이범용; 신지원; 박준국; 예경무 Abstract: The present invention relates to GFRAL antagonist antibodies and uses thereof, and more specifically, to anti-GFRAL antibodies comprising heavy chain CDR and light chain CDR of specific sequences, and antigen-binding fragments thereof. Anti-GFRAL antibodies are expected to be useful in the alleviation or treatment of cancer-related anorexia-cachexia syndrome, as well as adverse reactions caused by chemotherapeutics. https://scholar.dgist.ac.kr/handle/20.500.11750/59163 https://scholar.dgist.ac.kr/handle/20.500.11750/59162 Title: T 보조세포 유래의 세포외 소포체로 활성화된 세포독성 T 세포를 유효성분으로 포함하는 암 질환의 예방 또는 치료용 조성물 Author(s): 백문창; 정인성; 정도경; 류수연; 예경무; 신상희 Abstract: The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above. https://scholar.dgist.ac.kr/handle/20.500.11750/59162